針對肥胖症治療 來凱醫藥(2105.HK)宣佈LAE102美國I期臨牀試驗完成首位受試者給藥
2025年5月28日——來凱醫藥(2105.HK)宣佈,其自主研發針對ActRIIA的單克隆抗體LAE102,在美國針對肥胖症治療的一項I期臨牀試驗已完成首位受試者給藥。該試驗計劃於2025年9月完成主要研究階段。
同時,LAE102正在中國進行I期多劑量遞增(MAD)研究,來凱醫藥將按計劃在2025年9月底前完成初步數據。
“我們非常高興與肥胖及代謝疾病領域的全球領導者禮來公司的團隊合作,爲患者提供突破性療法。”來凱醫藥董事會主席兼首席執行官呂向陽博士表示,“方案獲批後,項目團隊僅用了七週就實現了首例受試者訪視,在十週內完成了首例受試者給藥。雙方團隊彰顯了卓越執行力,我們對此深感自豪,並感謝禮來團隊對加速LAE102臨牀開發的全力投入。”
LAE102是來凱醫藥自主研發針對ActRIIA的單克隆抗體,ActRIIA是在肌肉再生和脂肪代謝中發揮重要作用的受體。在臨牀前模型中,LAE102已顯示出增加肌肉並減少脂肪的效果。LAE102與GLP-1受體激動劑聯用可進一步減少脂肪並顯著降低GLP -1受體激動劑導致的肌肉流失,使LAE102成爲一種高質量體重控制候選藥物。
2024年4月,來凱醫藥獲得美國食品藥品監督管理局(FDA)就LAE102針對肥胖症治療的新藥臨牀試驗申請(IND)的批準。2024年11月,來凱醫藥與禮來公司(Eli Lilly and Company)達成一項臨牀合作,依託禮來的Catalyze360™ 引擎,支持和加速LAE102針對肥胖治療的全球臨牀開發。來凱醫藥保留LAE102的全球權益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.